126325-47-1

Basic information

• Product Name: 5-Amino-2-bromo-6-picoline
• Synonyms: 3-AMINO-6-BROMO-2-METHYLPYRIDINE;3-AMINO-6-BROMO-2-PICOLINE;6-BROMO-2-METHYL-PYRIDIN-3-YLAMINE;2-Bromo-5-amino-6-methylpyridine;6-Bromo-5-amino-2-picoline;6-BROMO-3-AMINO-2-PICOLINE (5-AMINO-2-BROMO-6-PICOLINE);5-AMINO-2-BROMO-6-PICOLINE (5-AMINO-2-BROMO-6-METHYLPYRIDINE);6-bromo-2-methylpyridine-3-amine
• CAS NO: 126325-47-1
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• EINECS: 251-156-6
• Product Categories: Pyridine;Pyridines;Boronic Acid;Amino-pyridine series;Heterocycle-Pyridine series
• Mol File: 126325-47-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 110-111℃
• Boiling Point: 284.4 °C at 760 mmHg
• Flash Point: 125.8 °C
• Appearance: Off-white/Solid
• Density: 1.593 g/cm³
• Vapor Pressure: 0.00298mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.45±0.10(Predicted)
• CAS DataBase Reference: 5-Amino-2-bromo-6-picoline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2-bromo-6-picoline(126325-47-1)
• EPA Substance Registry System: 5-Amino-2-bromo-6-picoline(126325-47-1)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-41-37/38-22
• Safety Statements: 26-36-39
• Hazardous Substances Data: 126325-47-1(Hazardous Substances Data)

Usage

Chemical Properties

crystalline powder

Uses

5-Amino-2-bromo-6-picoline is a useful research intermediate.

InChI:InChI=1/C6H7BrN2/c1-4-5(8)2-3-6(7)9-4/h2-3H,8H2,1H3

Upstream product

• 3430-10-2 2-methyl-3-pyridinamine 
• 22282-96-8 6-bromo-2-methyl-3-nitro-pyridine 

Downstream Products

• 1956379-02-4 5,7-dibromo-1H-pyrazolo[4,3-b]pyridine 
• 1079054-78-6 5-amino-6-methylpicolinonitrile 
• 1400926-88-6 (7aS,9R,11aS)-11a-benzyl-9-ethyl-9-hydroxy-6,7,7a,8,9,10,11,11a-octahydro-5H-dibenzo[a,c]cycloheptene-3-carboxylic acid (6-bromo-2-methyl-pyridin-3-yl)-amide 
• 897732-75-1 2-methyl-6-(methylsulfonyl)pyridin-3-amine 
• 944317-27-5 6-bromo-3-chloro-2-methylpyridine 
• 42451-07-0 6-ethyl-2-methylpyridin-3-ol 
• 1227628-78-5 5-bromo-1H-pyrazolo[4,3-b]pyridine 

Relevant articles and documents

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.